Drugging the undruggable - Parabilis Medicines

Our first video episode with a guest features Mathai Mammen, MD, PhD, a pharmaceutical R&D veteran who previously led global R&D at Johnson & Johnson and research at Merck. Now as CEO of Parabilis Medicines, he’s tackling what has long been considered impossible: treating untreatable conditions.

Parabilis has pioneered the Helicon platform, a breakthrough peptide technology that accesses disease-causing proteins inside cells that make up about 80% of human biology yet traditional drugs cannot reach. By leveraging thousands of unnatural amino acids and AI, they’ve created what Mathai calls a “perfectly hybrid company” that couldn’t have existed even a decade ago.

Their lead program achieved impressive results in desmoid tumors with a 100% disease control rate and their pipeline includes two prostate cancer programs.

His advice to innovators? Aim high. Science and AI have evolved in amazing ways and now is the time to do something really big to change the world.

This episode is a must-listen for anyone interested in platform technologies, AI-driven drug discovery, or building biotech companies that overcome previously unsolvable obstacles.